Sage Therapeutics IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Sage Therapeutics | SAGE - NASDAQ |
$17.00-$18.00 |
$18.00 |
$27.00 | 5 million | 7/18/2014 |
J.P. Morgan, Goldman Sachs & Co. |
Co-Manager(s): Leerink Partners, Canaccord Genuity |
Health Care |
Filing(s): Filed 2014-06-18 Terms Added 2014-07-08 Amended Terms 2014-07-17
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Sage Therapeutics, and our comprehensive analysis, click "Buy Market Research".
Sage Therapeutics Quote & Chart - Click for current quote -
SAGE
About Sage Therapeutics (adapted from Sage Therapeutics prospectus):
They are a biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders, where there are inadequate or no approved existing therapies.
This description is adapted from Sage Therapeutics prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as Sage Therapeutics "SAGE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved